These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10770528)

  • 1. Pleural fibrosis associated with dihydroergocryptine treatment.
    Oechsner M; Groenke L; Mueller D
    Acta Neurol Scand; 2000 Apr; 101(4):283-5. PubMed ID: 10770528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R; Manian P; Gauthier P; Jankovic J
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alopecia induced by dopamine agonists.
    Tabamo RE; Di Rocco A
    Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
    Driver-Dunckley E; Samanta J; Stacy M
    Neurology; 2003 Aug; 61(3):422-3. PubMed ID: 12913220
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 11. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole and somnolence.
    Shuster J
    Nursing; 2000 Aug; 30(8):81. PubMed ID: 10983129
    [No Abstract]   [Full Text] [Related]  

  • 16. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M; MacIver DH
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of dopamine agonists.
    Lam YW
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):17S-25S. PubMed ID: 10641988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.